Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label Study of ABSK141 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients With KRAS G12D Mutant Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I/II, Open-Label Study of ABSK141 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients With KRAS G12D Mutant Advanced Solid Tumors

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KRAS protein inhibitors (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions; First in man

Most Recent Events

  • 01 Jan 2026 New trial record
  • 24 Dec 2025 According to an Abbisko Therapeutics media release, company announced that the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ABSK141, an oral, highly potent and selective small-molecule KRAS G12D inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS G12D mutations.
  • 01 Dec 2025 According to an Abbisko Therapeutics media release, company has cleared Investigational New Drug (IND) application for ABSK141, for the treatment of patients with advanced solid tumors harboring KRAS G12D mutations.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top